Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.49 |
| ▸ | BRAF | P15056 | 11/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25227281 | 0.92 | KDR (0.47) | KDRBRAFMAPK8MAPK10MAPK14 | |
| SCHEMBL25277842 | 0.91 | KDR (0.42) | KDRBRAF | |
| SCHEMBL31388470 | 0.91 | KDR (0.51) | KDRBRAFMAPK8MAPK10MAPK14 | |
| SCHEMBL31388509 | 0.91 | KDR (0.46) | KDRBRAFMAPK8MAPK10MAPK14 | |
| SCHEMBL31388465 | 0.90 | KDR (0.49) | KDRBRAF | |
| SCHEMBL31388488 | 0.90 | KDR (0.48) | KDRBRAF | |
| SCHEMBL25422345 | 0.90 | KDR (0.51) | KDRBRAF | |
| SCHEMBL31388485 | 0.89 | KDR (0.46) | KDRBRAF | |
| SCHEMBL31388467 | 0.89 | KDR (0.47) | KDRBRAF | |
| SCHEMBL31388466 | 0.89 | KDR (0.50) | KDRBRAFMAPK8MAPK10MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4448492-B1 | COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | REGLAGENE INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12404242-B2 | Compositions and methods for making and using small molecules in the treatment of cancer | REGLAGENE, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250109105-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | REGLAGENE, INC. | 2025-04-03 | — | — | US | disclosed |
| EP-4448492-A1 | COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | Reglagene, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023111996-A1 | COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | REGLAGENE HOLDING, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109105-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | CD47, RB1, TP53 | KDR 3225/4885BRAF 107/4885MAPK8 3040/4885 |
| US-12404242-B2 | Compositions and methods for making and using small molecules in the treatment of cancer | CD47, RB1, TP53 | KDR 3225/4885BRAF 107/4885MAPK8 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.